STOP-JIA Starts To Evaluate The Most Effective Treatment

March 22, 2016

DURHAM, N.C., March 22, 2016 /PRNewswire-USNewswire/ — The Childhood Arthritis and Rheumatology Research Alliance (CARRA), Inc. announced today that the first two patients had enrolled in the Start Time Optimization in Polyarticular Juvenile Idiopathic Arthritis (STOP-JIA) project. STOP-JIA aims to answer a critical question facing patients and doctors: “When is the best time to start biologic medications in polyarticular JIA?”

JIA is the most common pediatric rheumatic condition, affecting 1 to 4 in every 1000 children. More than half of affected children have a polyarticular form affecting many joints, and suffer worse outcomes and compromised quality of life. Symptoms of JIA include, but are not limited to joint pain, swelling and stiffness.

In STOP-JIA, patients, families, and their doctors will discuss and select one of 3 treatment plans developed and commonly used by pediatric rheumatologists which differ in the timing of when biologics are started. Patients will also contribute by answering surveys related to quality of life and burden of the disease and its treatments.

Visit PRNEWSWIRE.COM to view the full article.